{"article_title": "How Obamacare Made Hospira A Lucrative Target For Pfizer", "article_keywords": ["pfizer", "lucrative", "hospira", "obamacare", "target"], "article_url": "http://www.forbes.com/sites/brucejapsen/2015/02/06/how-obamacare-made-hospira-a-lucrative-target-for-pfizer/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Bruce Japsen", "og": {"site_name": "Forbes", "description": "The proposed $17 billion purchase by\u00a0Pfizer\u00a0(PFE) of generic injectable drug maker Hospira (HSP) became a lot more attractive thanks to the Affordable Care Act and the law\u2019s promise to bring cheaper versions of expensive biotech drugs to the U.S. market. Hospira has a fast-growing biosimilars business in Europe\u00a0where there is\u00a0already a [...]", "title": "How Obamacare Made Hospira A Lucrative Target For Pfizer", "url": "http://www.forbes.com/sites/brucejapsen/2015/02/06/how-obamacare-made-hospira-a-lucrative-target-for-pfizer/", "image": "http://blogs-images.forbes.com/brucejapsen/files/2015/02/98d336da0f13a2dece939a6a784d8f60_9850.jpg", "updated_time": "2015-02-08T19:42:29-05:00", "type": "article"}, "twitter": {"description": "The proposed $17 billion purchase by\u00a0Pfizer\u00a0(PFE) of generic injectable drug maker Hospira (HSP) became a lot more attractive thanks to the Affordable Care Act and the law\u2019s promise to bring cheaper versions of expensive biotech drugs to the U.S. market. Hospira has a fast-growing biosimilars business in Europe\u00a0where there is\u00a0already a [...]", "title": "How Obamacare Made Hospira A Lucrative Target For Pfizer", "image": "http://blogs-images.forbes.com/brucejapsen/files/2015/02/98d336da0f13a2dece939a6a784d8f60_9850.jpg", "creator": "@brucejapsen", "site": "@forbes", "card": "summary_large_image"}, "description": "The proposed $17 billion purchase by\u00a0Pfizer\u00a0(PFE) of generic injectable drug maker Hospira (HSP) became a lot more attractive thanks to the Affordable Care Act and the law\u2019s promise to bring cheaper versions of expensive biotech drugs to the U.S. market. Hospira has a fast-growing biosimilars business in Europe\u00a0where there is\u00a0already a [...]", "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/business", "section": "Business", "modified": "2015-02-08", "published": "2015-02-06", "id": "blogAndPostId/blog/post/2125-9850"}, "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "news_keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy"}, "article_summary": ""}